A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum

[1]  R. Dreicer,et al.  Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  F. Shepherd,et al.  Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. , 1996, European journal of cancer.

[3]  A. Harris,et al.  Phase II study of gemcitabine in patients with advanced pancreatic cancer. , 1996, British Journal of Cancer.

[4]  T. Kuzel,et al.  1152 Gemcitabine in the treatment of patients with advanced transitional cell carcinoma: A phase II study , 1995 .

[5]  A. Harris,et al.  Advanced breast cancer: a phase II trial with gemcitabine. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Roth.  Preliminary experience with paclitaxel in advanced bladder cancer. , 1995, Seminars in oncology.

[7]  B. Roth.  Palliative chemotherapy in advanced bladder cancer. , 1995, Seminars in oncology.

[8]  R. Dreicer,et al.  Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Neijt,et al.  Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. , 1994, Journal of the National Cancer Institute.

[10]  M. Dimopoulos,et al.  Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy. , 1994, The Journal of urology.

[11]  A. Ceribelli,et al.  Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  D. V. Von Hoff,et al.  Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. , 1994, European journal of cancer.

[13]  Y Z Xu,et al.  Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation. , 1992, Cancer research.

[14]  L. Hertel,et al.  Action of 2',2'-difluorodeoxycytidine on DNA synthesis. , 1991, Cancer research.

[15]  S. Mineishi,et al.  A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Igawa,et al.  Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. , 1990, The Journal of urology.

[17]  L. Hertel,et al.  Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). , 1990, Cancer research.

[18]  N. Geller,et al.  Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse , 1989, Cancer.

[19]  I. Tannock,et al.  M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. , 1989, The Journal of urology.

[20]  V. Heinemann,et al.  Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. , 1988, Cancer research.